Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.55 |
| ▸ | MAPT | P10636 | 9/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 8/20 | 0.41 |
| ▸ | USP2 | O75604 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18220245 | 0.94 | MAPT (0.55) | ALDH1A1MAPTLMNAMAPK1HPGD | |
| SCHEMBL25609268 | 0.90 | ALDH1A1 (0.61) | ALDH1A1MAPTLMNAMAPK1HPGD | |
| SCHEMBL17120624 | 0.86 | KMT2A (0.54) | ALDH1A1MAPTLMNAMAPK1HPGD | |
| SCHEMBL18220134 | 0.86 | ALDH1A1 (0.63) | ALDH1A1MAPTLMNAMAPK1HPGD | |
| SCHEMBL17120684 | 0.85 | LMNA (0.44) | ALDH1A1MAPTLMNAMAPK1KDM4E | |
| SCHEMBL17120877 | 0.85 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAMAPK1HPGD | |
| SCHEMBL17120861 | 0.85 | ALDH1A1 (0.54) | ALDH1A1MAPTLMNAMAPK1HPGD | |
| SCHEMBL17120886 | 0.85 | ALDH1A1 (0.48) | ALDH1A1MAPTLMNAMAPK1HPGD | |
| SCHEMBL17120798 | 0.85 | KMT2A (0.44) | ALDH1A1MAPTLMNAMAPK1KDM4E | |
| SCHEMBL17120671 | 0.83 | PRMT5 (0.38) | ALDH1A1MAPTLMNAMAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3119761-B1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
| US-20210369873-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200123118-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-04-23 | — | — | US | disclosed |
| US-10370345-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-06 | — | — | US | disclosed |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
| WO-2015143185-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | ALDH1A1 4151/4885MAPT 25/4885LMNA 1263/4885 |
| US-20200123118-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | ALDH1A1 4151/4885MAPT 25/4885LMNA 1263/4885 |
| US-20210369873-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY | S100B, FABP7, CRYAB | ALDH1A1 4102/4885MAPT 38/4885LMNA 270/4885 |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | ALDH1A1 4151/4885MAPT 25/4885LMNA 1263/4885 |
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | ALDH1A1 4151/4885MAPT 25/4885LMNA 1263/4885 |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, APBA1, CRYAA | ALDH1A1 4226/4885MAPT 26/4885LMNA 1283/4885 |
| US-10370345-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | ALDH1A1 4151/4885MAPT 25/4885LMNA 1263/4885 |
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | ALDH1A1 4151/4885MAPT 25/4885LMNA 1263/4885 |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | APP, APBA1, CRYAA | ALDH1A1 4226/4885MAPT 26/4885LMNA 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.